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Background: The biological processes and molecular mechanisms underlying miR-107 remain unclear in gastric cancer
(GC). In this study, we aimed to investigate the expression, biological functions and mechanisms of miR-107 in GC.
Methods: Quantitative real-time RT-PCR was used to test miR-107 expression. MTT and colony formation assays were
conducted to explore the potential function of miR-107 in human GC cell line SGC7901. The target gene was determined
by bioinformatic algorithms, dual luciferase reporter assay, RT-PCR and Western blot.
Results: Expression of miR-107 was significantly elevated in GC cell line than that in gastric epithelial cell line(p = 0.012).
We found that miR-107 inhibitor transfection significantly decreased the proliferation of GC cell line, and clone formation
rate of miR-107 inhibitor transfected group was significantly lower than that of control group. Luciferase assays using a
reporter carrying a putative miR-107 target site in the 3′untranslated region (3′-UTR) of cyclin dependent kinase 8 (CDK8)
revealed that miR-107 directly targets CDK8. The expression level of CDK8 mRNA and protein in miR-107 inhibitor
transfected GC cell line was significantly decreased compared with control group.
Conclusion: Our findings indicate that miR-107 is upregulated in GC and affects the proliferation of GC cells, partially
through the regulation of CDK8.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_164
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Gastric cancer (GC) is the fourth most common malignancy
and the second most common cause of death from cancer
in the world [1]. In general, GC has a 5‑year overall survival
rate of ~15% and for patients with advanced GC, the
median overall survival is <1 year [2]. Considering these
statistics, increased research into potential preventative
methods for GC is required, as well as improved early
detection and more effective treatments.
MicroRNAs (miRNAs) are a recently discovered class
of small (approximately 18–24 nucleotides in length),
noncoding regulatory RNAs that negatively regulate gene
expression at the posttranscriptional and/or translational
level. miRNAs can trigger cleavage of target mRNAs
or inhibit protein translation through sequence-specific* Correspondence: qd_lvwenping@126.com
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unless otherwise stated.interactions with the 3′-untranslated regions (3′-UTRs) of
the target mRNAs [3-5]. Although the full extent of
the biological functionalities of miRNAs has yet to be
identified, they have been suggested to act as intrinsic
regulators of many cellular processes including cell
invasion, differentiation, proliferation, and apoptosis
[6,7]. Furthermore, aberrant expression of miRNAs has
been linked to the development and progression of cancer
and has been shown to have prognostic significance
[8]. Accumulating evidence shows that microRNA-107
(miR-107) is one of the oncogenic RNAs, and overexpres-
sion of these RNAs has been reported in several types
of human malignant solid tumors, including gastric,
esophageal, pancreatic and colorectal cancer [9-12].
Previously, Inoue et al. found that the mean expression
level of miR-107 was significantly higher in the GC tissues
compared to that of normal tissues. In the comparison of
clinicopathological factors, miR-107 expression showed
significant association with depth of tumor invasion, lymphtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tailed mechanisms of miR-107 were fewly investigated
in GC.
Cyclin dependent kinase 8 (CDK8) locating on chromo-
some13q12 has five transcripts and only one transcript
encodes protein product containing 464 amino acid
residues (molecular weight 53.2 kD). CDK8 has important
function on the regulation of gene transcription [14].
Recent studies suggest that CDK8 is important in the
process of tumor development [15]. CDK8 plays a key
role in the regulation of cell cycle and cell growth on
post-transcriptional level, and promotes the development
and progression of colorectal cancer [16]. We found
that miR-107 might modulate CDK8 using online pre-
diction software Target Scan. In our study, we sought
to investigate the crucial role of miR-107 in GC. We
identified that miR-107 could regulate proliferation of
GC by targeting CDK8.
Methods
Cell lines
Human GC cell line SGC7901 and a non-malignant
gastric epithelium cell line GES-1 were obtained from
the Chinese Academy of Sciences (Shanghai, China),
and cultured in RPMI-1640 medium with 10% FBS.
HEK-293 cell was cultured in Dulbecco’s modified Eagle’s
medium with 10% FBS. All cell lines were incubated
at 37°C with 5% CO2.
Total RNA extraction and qRT-PCR
Total RNA was isolated by TRIzol Reagent (Invitrogen,
CA, USA). SYBR Premix Ex Taq (Takara, Tokyo, Japan)
was used to assess gene expression on ABI Stepone plus
(ABI, CA, USA). miRNA was isolated with All-in-one
microRNA extraction kit (GeneCopoeia, CA, USA).
Primers for CDK8: forward, 5′-GCCGGCATAGACGCG
TGCTGCATCGGAATC-TTGTC-3′ and reverse, 5′-AT
CCTTTATTAAGCTTACCACATACAAAGACAAATGC
TT-3′.
Primers for GAPDH: forward, 5′-ACGGATTTGGTC
GTATTGGGC-3′, and reverse, 5′-TTGACGGTGCCA
TGGAATTTG-3′. Primers for miR-107 and U6 were
obtained from GeneCopoeia. The expression of CDK8
was normalized with GAPDH, and the expression of
miR-107 was normalized with U6.
MTT assay for proliferation activity
SGC7901 cells was cultured in 25 cm2 culture flask to
approximately 80%-90% density collected by digestion
and centrifugation, and then seeded into 96 well plates at
1,000 cells/well. 96-well plate was placed in cell culture
incubator until cell monolayer reaches 40%-50% density.
MiR-107 inhibitor was transfected into cells according to
Invitrogen Lipofectamine reagent instructions. 20 μl MTTsolution (5 mg/ml) was added daily for 4 days. Supernatant
was discarded and 150 μl DMSO (dimethyl sulfoxide)
was added to each well. Then plates were placed on
low-speed shaker for 10 min to fully dissolve the
crystals. Absorbance at 490 nm was measured by the
multi-plate reader. Experiment was performed with
sextuplicates and repeated for 3 times.
Colony-forming unit assay
miR-107 inhibitor or control was transfected into
SGC7901 cells at 100 nM concentrations. 48 h later
transfected cells were seeded into 6-well plates as 500
cell/well with triplicate and incubated at 37°C, 5% CO2
for 7 days until visible cloning were observed in the
dish. Culture medium was discarded. Each well was
washed with PBS twice carefully. Then cells were fixed
with 4% paraformaldehyde for 10 min and stained with
0.1% crystal violet. After washed with running water
three times and dried at room temperature, each well
was observed and photographed. Cell colonies with
more than 50 cells were counted under the micro-
scope. Clone formation rate was calculated as following
formula: Clone formation rate = number of formed colony/
number of seeded cells × 100%.
miR-107 target gene prediction and 3′-UTR plasmid
vectors construction
miRNA target genes were predicted using online pre-
diction software miRanda, TargetScan and PicTar. 3′-UTR
region of CDK8 including miR-107 targeting sequence was
amplified using PCR amplification. Upstream primer: 5′-G
CCGGCATAGACGCGTGCTGCATCGGAATC-TTG
TC-3′, downstream primer: 5′-ATCCTTTATTAAG
CTTACCACATACAAAGACAAATGCTT-3′ (Mlu I,
Hind III restriction sites were underlined). Target se-
quence after T-A clone was sub-cloned into the vec-
tor pMIR and inserted into the downstream of firefly
luciferase gene. This recombinant vector was named
as pMIR-REPORT. All constructed plasmids were
validated by restriction analysis and DNA sequencing.
Luciferase report gene detection
HEK293 cells in logarithmic growth phase were seeded
into 96-well culture plate, incubated at 37°C, 5% CO2
for 24 h, and co-transfected with pMIR-REPORT and
miR-107 mimics (or NC) using Lipofectamine 2000. Ex-
periment was performed with sextuplicates and re-
peated for 3 times. Detection was performed following
instruction of dual luciferase reporter gene assay kit.
Cell culture medium was discarded after 24 h transfec-
tion. Wells were washed three times with PBS and
treated by 20 μl cell lysis buffer for 15 min at room
temperature. 100 μl firefly luciferase detection solution
was added to detect firefly luciferase activity, then 100 μl
Figure 2 miR-107 promoted GC cell line proliferation.
a Inhibition of miR-107 significantly decreased cell proliferation in
SGC7901 cells. b The proportion of apoptotic SGC7901 cells induced
by miR-107 inhibitor was significantly greater than that induced by
the negative control. *P < 0.05.
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renilla luciferase activity. Luciferase activity (C) = firefly
luciferase/renilla luciferase activity. Relative luciferase ac-
tivity was calculated in each group.
Western blotting
Total protein was extracted from GC cell line. The con-
centration of proteins was measured by BCA protein
assay kit (Pierce, IL, USA). Proteins were separated by
10% SDS-PAGE gel and transferred to polyvinylidene
difluoride(PVDF) membrane (Millipore, MA, USA). The
membrane was first incubated with specific primary
antibodies, then with secondary antibodies labeled with
HRP and detected by ECL.
Statistical methods
Experimental data was showed as mean ± SD. Two groups
were compared using t-test comparison and multi-groups
were compared using variance analysis by SPSS18.0 statis-
tical software. P < 0.05 indicates significant difference.
Results
miR-107 was elevated in GC cell line SGC7901
qRT-PCR was used to detect the expression of miR-107 in
GC cell line, SGC7901, and a gastric epithelial cell line,
GES-1. Expression of miR-107 was significantly elevated
in GC cell line, SGC7901 (P = 0.012, shown in Figure 1).
miR-107 promoted GC cell line proliferation
We investigated the effect of miR-107 on the proliferation
of GC cell line SGC7901. We found that miR-107 inhibi-
tor transfection significantly decreased the proliferation of
SGC7901 (shown in Figure 2a). We further explored the
effect of miR-107 on apoptosis and found that apoptosis
was increased dramatically in SGC7901 cells 72 h after
transfection of miR-107 inhibitor (shown in Figure 2b),
suggesting that miR-107 might function as an antiapopto-
tic factor in human GC cells.Figure 1 miR-107 was elevated in GC cell line. *P < 0.05.miR-107 inhibitor decreased GC cell line SGC7901 clone
formation rate
Clone formation rate of miR-107 inhibitor transfected
group was significantly lower than that of control group,
demonstrating that miR-107 inhibitor significantly inhib-
ited GC cell line SGC7901 colony formation (P < 0.05,
shown in Figure 3).
CDK8 was a direct target of miR-107
Comparison of luciferase activity in experimental group
with negative control group showed that luciferase activ-
ity in SGC7901 cells cotransfected with pMIR-REPORT
and miR-107 mimics was 38.9% of that in pMIR-
REPORT and NC cotransfected group (5.02 ± 2.11 vs.
12.87 ± 6.37, P < 0.05, shown in Figure 4a). This data
showed that there was specific binding between miR-107
and 3′-UTR in CDK8 gene. CDK8 mRNA expression
level was significantly decreased in miR-107 inhibitor
transfected SGC7901 cells compared with control group
Figure 4 CDK8 was a direct target of miR-107. a: The relative
luciferase activity (firefly/renilla) was measured in HEK293 cells after
cotransfection of the CDK8 luciferase construct with either miR-107
mimics or NC. b: CDK8 mRNA level was detected by RT-PCR in SGC7901
cells transfected with miR-107 inhibitor or the control. c: CDK8 protein
level was detected by Western blotting in SGC7901 cells transfected
with miR-107 inhibitor or the control. *P< 0.05.
Figure 3 miR-107 inhibitor inhibited cell colony formation.
*P < 0.05.
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sion measured by Western blotting in miR-107 inhibitor
transfected SGC7901 cells was significantly decreased
compared with control group (shown in Figure 4c). These
results indicated that miR-107 suppressed CDK8 expres-
sion posttranscriptionally.
Down regulation of CDK8 attenuated the oncogenic
effect of miR-107
Further investigations were performed to study whether
down regulation of CDK8 could attenuate the oncogenic
effect of miR-107. MTT assay showed that down regulation
of CDK8 by siRNA for CDK8 could significantly attenuate
the oncogenic effect of miR-107 (shown in Figure 5), sug-
gesting that miR-107 promoted the proliferation of GC cells
partially by targeting CDK8.
Discussion
It is generally accepted that the development of GC, like
other cancers, involves multiple steps, including the ac-
cumulation of genetic and epigenetic changes. However,
the precise mechanism underlying gastric carcinogenesis
remains unclear. Therefore, it has been a global research
hotspot to looking for new therapeutic targets for GC
treatment.
Accumulating evidence has indicated that aberrant
expression of miRNAs may be a common mechanism
involved in the development of various cancers [3]. In-
vestigation of cancer-specific miRNAs and their targets
is necessary for further elucidation of their role in the
pathogenesis of tumors, and may be important for the
design of novel therapeutic targets [6,8,17]. Although
miRNAs have been widely studied in different types of
cancers, the knowledge of the aberrant expression and
potential function of miRNAs in GC is largely lacking.
Accumulating evidence shows that miR-107 is one of
the oncogenic RNAs, and overexpression of these RNAs
has been reported in several types of human malignantsolid tumors. Previously, Inoue et al. found that the mean
expression level of miR-107 was significantly higher in the
GC tissues compared to that of normal tissues. In the
Figure 5 Down regulation of CDK8 attenuated the oncogenic
effect of miR-107. *P < 0.05 compared with control. #P < 0.05
compared with miR-107 mimics group.
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pression showed significant association with depth of
tumor invasion, lymph node metastasis and tumor stage.
In Kaplan-Meier survival curve analysis, OS and DFS of
patients with high miR-107 expression were significantly
worse than those of patients with low miR-107 expression.
In the Cox multivariate analysis, it was shown that
miR-107 expression in GC tissues was an independent
prognostic factor for OS and DFS. Their results indicate
that miR-107 may be useful as an effective biomarker for
prediction of a poor prognosis in GC patients [13]. How-
ever, the detailed mechanisms of miR-107 were fewly
investigated in GC. Previously, Feng et al. found that miR-
107 targeted cyclin-dependent kinase 6 (CDK6) expres-
sion, induced cell cycle G1 arrest and inhibited invasion in
GC cells [18]. Li et al. found that upregulation of miR-107
induced proliferation in GC cells by targeting the tran-
scription factor FOXO1 [19]. In the present study, we vali-
dated that the expression of miR-107 was significantly
increased in GC cell line compared with normal controls.
Consistent with previous findings from other cancers, such
as esophageal cancer, pancreatic cancer and colorectal can-
cer [9-12], in GC, we also found that miR-107 could
remarkably promote cell proliferation and suppress apop-
tosis. In addition, we found that clone formation rate of
miR-107 inhibitor transfected group was significantly lower
than that of control group, demonstrating that miR-107 in-
hibitor significantly inhibited GC cell line colony forma-
tion. Thus, our data suggested that miR-107 might play an
important role in GC development.
As we know, miRNA functions through interacting
with target genes thus the key to explore the mechanism
of miRNA is to study the interaction between miRNA
and its target genes. In this study, CDK8 was predicted
to be the target gene of miR-107 by online biologicalsoftware, then luciferase reporter vectors containing
CDK8 gene 3′-UTR region with miR-107 binding site
was constructed and specific binding between miR-107
and CDK8 was verified. The expression level of CDK8
mRNA and protein in miR-107 inhibitor transfected GC
cell line was significantly decreased compared with con-
trol group,, indicating that miR-107 suppressed CDK8 ex-
pression posttranscriptionally. CDK8 is a member of CDK
family (CDKs), which is a group of serine-threonine pro-
tein kinase and consists of 10 members with different
homology. In the past decade, It has been showed that
CDKs were excessively activated in different tumors [20].
Preclinical studies have proved that CDKs can promote
gene transcription, cell differentiation and angiogenesis
[21]. In our study, MTT assay showed that down regula-
tion of CDK8 by siRNA could significantly attenuate the
oncogenic effect of miR-107, suggesting that miR-107 pro-
moted the proliferation of GC cells partially by targeting
CDK8.
Conclusion
In conclusion, our findings indicate that miR-107 is up-
regulated in GC and affects the proliferation of GC cells,
partially through the regulation of CDK8. Thus, the
identification of the role of miR-107 as an oncogene
through targeting CDK8 in GChelps us to further elucidate
the potential molecular mechanisms of GC development.
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